MG
Live price temporarily unavailable.
Price history
MacroGenics (MGNX) is a Health Care company in the Russell 2000. Latest news and coverage below.
MacroGenics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $91.9M | $157.7M | $60.1M | $64.2M | $104.9M | $77.4M | $151.9M | $58.7M | $150.0M | $149.5M |
| Growth (year over year) | −8.9% | +71.7% | −61.9% | +6.8% | +63.4% | −26.2% | +96.2% | −61.3% | +155.3% | −0.3% |
| Gross profit | — | — | — | $64.2M | $104.9M | $74.8M | $148.6M | $58.1M | $149.1M | $149.5M |
| Gross margin | — | — | — | 100.0% | 100.0% | 96.6% | 97.8% | 98.9% | 99.4% | 100.0% |
| Operating income | −$60.0M | −$22.1M | −$171.2M | −$177.2M | −$131.1M | −$202.8M | −$121.4M | −$168.2M | −$110.6M | −$72.8M |
| Operating margin | −65.3% | −14.0% | −284.8% | −276.0% | −125.0% | −261.9% | −79.9% | −286.4% | −73.7% | −48.7% |
| Net income | −$58.5M | −$19.6M | −$171.5M | −$151.8M | −$129.7M | −$202.1M | −$119.8M | −$9.06M | −$67.0M | −$74.6M |
| Net margin | −63.7% | −12.4% | −285.2% | −236.5% | −123.7% | −261.0% | −78.8% | −15.4% | −44.7% | −49.9% |
| EPS (diluted) | −$1.69 | −$0.54 | — | — | −$2.47 | −$3.37 | −$1.95 | −$0.15 | −$1.07 | −$1.18 |
| Balance sheet | ||||||||||
| Cash and equivalents | $84.1M | $211.7M | $220.1M | $126.5M | $181.1M | $123.5M | $108.9M | $101.0M | $182.8M | $57.2M |
| Total assets | $311.3M | $373.9M | $332.1M | $312.5M | $378.7M | $335.2M | $280.5M | $298.4M | $261.7M | $256.8M |
| Total liabilities | $42.5M | $74.6M | $89.3M | $81.9M | $82.9M | $95.6M | $138.5M | $145.8M | $145.6M | $201.3M |
| Shareholders' equity | $268.8M | $299.2M | $242.9M | $230.6M | $295.9M | $239.6M | $142.0M | $152.6M | $116.1M | $55.6M |
| Cash flow | ||||||||||
| Operating cash flow | −$43.7M | $14.4M | −$153.2M | −$134.3M | −$111.9M | −$143.8M | −$87.0M | −$78.2M | −$68.4M | −$81.0M |
| Capital expenditure | $11.4M | $29.4M | $25.0M | $4.29M | $5.91M | $6.20M | $3.62M | $1.76M | $3.71M | $1.91M |
| Free cash flow | −$55.1M | −$15.0M | −$178.2M | −$138.6M | −$117.8M | −$150.0M | −$90.6M | −$80.0M | −$72.1M | −$83.0M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $110.7M | $19.4M | $13.2M | $6.87M | $72.8M | $56.6M | $20.8M | $32.8M |
| Growth (year over year) | +964.8% | +80.5% | +44.9% | −36.4% | −34.2% | +192.5% | +57.5% | +378.0% |
| Gross profit | $110.5M | $19.1M | $13.2M | $6.87M | $72.8M | $56.6M | — | — |
| Gross margin | 99.8% | 98.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | $54.2M | −$52.8M | −$42.6M | −$43.2M | $18.6M | −$5.63M | −$33.4M | −$13.9M |
| Operating margin | 48.9% | −273.0% | −323.1% | −629.3% | 25.6% | −9.9% | −161.0% | −42.2% |
| Net income | $56.3M | −$15.4M | −$41.0M | −$36.3M | $16.8M | −$14.2M | −$36.8M | $19.5M |
| Net margin | 50.9% | −79.7% | −311.1% | −527.7% | 23.1% | −25.0% | −177.0% | 59.4% |
| EPS (diluted) | $0.90 | −$0.24 | −$0.65 | −$0.57 | $0.27 | −$0.23 | −$0.58 | $0.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $179.6M | $182.8M | $145.6M | $130.7M | $80.1M | $57.2M | $66.5M | $113.9M |
| Total assets | $264.5M | $261.7M | $224.6M | $245.4M | $270.8M | $256.8M | $217.9M | $345.4M |
| Total liabilities | $144.4M | $145.6M | $145.4M | $198.8M | $203.8M | $201.3M | $196.7M | $302.5M |
| Shareholders' equity | $120.1M | $116.1M | $79.1M | $46.6M | $67.0M | $55.6M | $21.2M | $42.9M |
| Cash flow | ||||||||
| Operating cash flow | $60.2M | −$38.4M | −$46.9M | −$47.0M | −$30.2M | $43.0M | −$35.8M | −$40.7M |
| Capital expenditure | $592.0K | $620.0K | $529.0K | $715.0K | $426.0K | $244.0K | $344.0K | $806.0K |
| Free cash flow | $59.6M | −$39.0M | −$47.4M | −$47.7M | −$30.6M | $42.8M | −$36.2M | −$41.6M |
From MacroGenics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About MacroGenics
- Headquarters
- Rockville, Maryland From SEC filings, Oct 2026
Recent News (2)
-
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
-
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the tre…
Other Health Care companies to compare with MGNX
- MDXH MDxHealth
- MEDP Medpace Holdings
- MENS Jyong Biotech
- MESO Mesoblast
- MGTX Meiragtx Holdings PLC
- MGX Metagenomi Therapeutics
- MIRM Mirum Pharmaceuticals Inc
- MIST Milestone Pharmaceuticals